PET/CT superior to MRI for detecting spinal bone metastases
Gallium-68 (Ga-68) DOTATATE PET/CT appears to be the best approach for detecting spinal bone metastases in patients with certain neuroendocrine tumors, according to researchers at the National Institutes of Health (NIH) in Bethesda, MD.
In a study of patients with pheochromocytomas and paragangliomas (PPGLs), the group found the approach was superior to F-18 FDG-PET/CT, MRI of the spine, whole-body CT, and whole-body MRI. The finding is significant regarding efforts to prevent serious complications in these patients, noted lead author Abhishek Jha, MD, and colleagues.
“Bone metastases weaken and destroy skeletal tissue...
Source: AuntMinnie.com Headlines - April 23, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Radiation Oncology Source Type: news
Car accident as a trigger for reverse takotsubo-like cardiomyopathy with paraganglioma: case report and literature review - Dai L, Zhou N, Zhou K, Zhang F, Chen F.
Paraganglioma (PGL), which may cause acute Takotsubo-like cardiomyopathy (TLC), is a rare neuroendocrine neoplasm derived from various body sites. TLC has been associated with excessive catecholamine secretion and shares the same cardiac presentation with... (Source: SafetyLit)
Source: SafetyLit - December 5, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Clonidine Suppression Test for a Pheochromocytoma Diagnosis Clonidine Suppression Test for a Pheochromocytoma Diagnosis
A new study evaluates the potential role of the clonidine suppression test in the assessment of suspected pheochromocytoma/paraganglioma.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Pheochromocytoma and Paraganglioma Incidence Over 70 Years Pheochromocytoma and Paraganglioma Incidence Over 70 Years
Medical advances have led to improvements in the detection and management of these rare neuroendocrine tumors, but knowledge gaps remain.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Lenvatinib in Metastatic Pheochromocytoma and Paragangliomas Lenvatinib in Metastatic Pheochromocytoma and Paragangliomas
Is lenvatinib an effective therapeutic option for the metastatic form of these rare neuroendocrine tumors?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Management of Pheochromocytomas and Paragangliomas Management of Pheochromocytomas and Paragangliomas
The perioperative management of these rare neuroendocrine tumors requires a multidisciplinary approach. Find out what there is to know.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Paraganglioma vs Pheochromocytoma
What Is the Difference Between Paraganglioma and Pheochromocytoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 25, 2021 Category: General Medicine Source Type: news
Head and Neck Paragangliomas Caused by SDHAF2 Mutation Head and Neck Paragangliomas Caused by SDHAF2 Mutation
What role did genetic testing play in diagnosing this case of head and neck paragangliomas?Journal of the Endocrine Society (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 15, 2020 Category: Radiology Tags: Diabetes & Endocrinology Journal Article Source Type: news
Lantheus Takes a Dive into Pharma with Proposed Acquisition
Lantheus Holdings is expanding its presence in the world of radiopharmaceutical diagnostics through a newly-proposed acquisition. On Wednesday, the North Billerica, MA-based company announced it would acquire Progenics Pharmaceuticals, an oncology company developing solutions to find, fight, and follow cancer in an all-stock transaction.
The transaction has been unanimously approved by the Boards of Directors of both companies.
Under the terms of the agreement, Lantheus Holdings will acquire all of the issued and outstanding common shares of Progenics stock at a fixed exchange ratio. Progenics shareholders will receive 0.2...
Source: MDDI - October 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Imaging Source Type: news
Upstate hosts International Conference on Pheo Para
Conference will host what is expected to be the largest single gathering of patients who have battled pheochromocytoma and paraganglioma, a rare condition marked by cancerous tumors. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - June 6, 2019 Category: Universities & Medical Training Source Type: news
